Cencora stock
Price history
−3.48% over the period1 year: from $365.00 (November 17, 2025) to $352.31 (November 17, 2026), −3.48%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $352.31 |
| October 30, 2026 | $330.84 |
| September 30, 2026 | $300.25 |
| August 31, 2026 | $323.60 |
| July 31, 2026 | $311.34 |
| June 30, 2026 | $282.98 |
| May 29, 2026 | $269.36 |
| April 30, 2026 | $308.01 |
| March 31, 2026 | $314.14 |
| February 27, 2026 | $372.14 |
| January 30, 2026 | $359.22 |
| December 31, 2025 | $337.75 |
| November 28, 2025 | $368.93 |
| November 17, 2025 | $365.00 |
At a glance
The company
Sources and distributes pharmaceuticals, medical supplies and healthcare products to hospitals, pharmacies, clinics and other healthcare providers in the U.S. and internationally
Latest results
Quarter to September 30, 2026 · EPS $4.66 (estimate $4.57)
Next event
TickerLandia's take on Cencora
- Priced as usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 20 over its last 9 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 20 vs 28 (−29%) in a group of 11.
- Strong point: Market momentum (70/100 in its group). Weak point: Profitability (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.15% from the 52-week high
Analysts · 14 analysts
Average target$382.42+9.09% vs. price
Buy 10 · Hold 4 · Sell 0 · Buy
TickerLandia Fingerprint: Cencora
Compared with similar companies: strong momentum, low profitability, and low risk.
Financials and price compared with 11 companies in the medical distribution industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage43
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 20.0 23 Forward P/E 16.4 50 EV/EBITDA 13.0 32 Price/book 18.5 94 Price/sales 0.20 14 Profitabilitylow34
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 4.1% 23 ROA 3.6% 23 Operating margin 1.4% 14 ROE 129.0% 95 Net margin 1.0% 14 Earnings stabilityhigh61
How steady its margins were over the last five annual reports.
Metric Value Position in group Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 55 Margin variabilitycounts in reverse: lower means more earnings stability 0.3% 68 Growthaverage48
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +8.77% 59 Revenue growth (year over year) +5.50% 36 Financial strengthaverage41
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 9.54 77 Debt/equitycounts in reverse: lower means more financial strength 3.06 5 Current ratio 0.94 41 Dividendaverage49
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 26 years 77 Dividend yield 0.7% 45 Payout ratio 13.8% 25 Market momentumstrong70
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +17.14% 86 Relative strength (6 months) +35.88% 90 1-year return −3.96% 27 Distance from 200-day average +10.71% 76 Risklow34
How much the price swings.
Metric Value Position in group Volatility (60 days) 25.6% 25 Beta (1 year) 0.05 19 Maximum drawdown (12 months) 32.6% 58
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Cencora is priced as in the past and cheaper than similar companies
On the latest fiscal year's earnings (2026), Cencora's P/E today is 19.6, in line with the median of its last 9 fiscal years (20.4; between 12.2 and 50.5 from 2017 to 2026). Cencora's P/E (trailing 12 months): 20.0, −29% against the median of a group of 11 similar companies (28.2).
Compared with 11 similar companies
| Metric | Cencora | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 20.0 | Low | |
| Forward P/E | 16.4 | Middle | |
| Operating margin | 1.4% | Low | |
| ROE | 129.0% | High | |
| Debt/equity | 3.06 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Cencora. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$88.35B
Latest quarter · Q3 2026
Net income
$519.4M
Latest quarter · Q3 2026
Quarterly net margin
0.6%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $68.11B
- P/E
- 20.0
- EPS
- $17.85
- Volume
- 1.03M
- Daily trading
- €437.99M
- Dividend yield
- 0.70%
- Last ex-dividend on November 13, 2026
How Cencora is changing
All resultsRevenue grew 9.5% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 154% of net income
Shares outstanding down 6.9% in 5 years
Returns
Cencora returns with dividends
$1,000 invested in Cencora 5 years ago, on November 17, 2021, would be worth $2,998 today with dividends reinvested: +199.76% in total, +24.56% per year. On price alone it would be $2,826 (+182.59%).
| Period | Cencora | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +3.62% | −3.17% | $1,036 |
| 6 months | +36.03% | +0.11% | $1,360 |
| Year to date | +4.31% | +8.34% | $1,043 |
| 1 year | −2.73% | +11.15% | $973 |
| 3 years | +85.12% | +64.30% | $1,851 |
| 5 years | +199.76% | +58.18% | $2,998 |
| 10 years | +484.88% | +239.10% | $5,849 |
Over the last 6 months it has done better than 74% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Cencora: technical analysis
Cencora shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 6.5% below its all-time closing high ($374.75, November 25, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 58
- Between 30 and 70
- vs 200-session average
- +10.71%
Support and resistance
Price areas where Cencora has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$376.45+7.39%3 touches, last on March 2, 2026
- Resistance$358.25+2.19%2 touches, last on January 20, 2026
- Resistance$350.77+0.06%2 touches, last on January 6, 2026
- Last price$350.56
- Support$344.09−1.85%2 touches, last on October 15, 2026
- Support$335.62−4.26%4 touches, last on September 3, 2026
- Support$327.75−6.51%4 touches, last on April 20, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.05
- Volatility (60 sessions, annualised)
- 25.6%
- Largest fall in the last year
- −32.56%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Cencora: seasonality
Average monthly price change over 32 years
Over the last 32 years, the strongest month for Cencora has been January: +4.59% on average, positive in 24 years out of 31. The weakest has been August: −0.81% on average, positive in 20 years out of 32. November, the current month, has been positive in 22 years out of 31 (+3.38% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.59% | +4.79% | 24 of 31 |
| February | −0.34% | +0.94% | 17 of 31 |
| March | +0.80% | +2.78% | 18 of 31 |
| April | +1.76% | +2.00% | 18 of 31 |
| May | +1.70% | +1.68% | 19 of 32 |
| June | +2.90% | +0.97% | 18 of 32 |
| July | +1.42% | +2.40% | 18 of 32 |
| August | −0.81% | +0.58% | 20 of 32 |
| September | +2.67% | +0.28% | 17 of 32 |
| October | −0.24% | +1.71% | 19 of 32 |
| November | +3.38% | +6.60% | 22 of 31 |
| December | +1.84% | +0.26% | 17 of 31 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Cencora and its competitors
Operating a network that moves pharmaceuticals on a scale of $337.4 billion in revenue, Cencora sources and distributes drugs in the United States and abroad. Its U.S. business supplies generic and injectable medicines, over-the-counter products and home healthcare equipment to hospitals, retail and mail-order pharmacies, clinics and long-term care providers, and it also handles plasma, blood products and vaccines. Services range from pharmacy management and staffing to clinical trial support, data analytics for drug makers and supply management software. Products for companion and production animals are also part of the offer.
- Headquarters
- Conshohocken, United States
- Employees
- 47,000
- Founded
- 2001
- Chief executive
- Robert Mauch
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| CencoraCOR | $68.11B | 1.4% | 20.0 | +36.03% |
| Cardinal HealthCAH | $64.97B | 1.3% | 36.4 | +43.06% |
| McKessonMCK | $126.04B | 1.6% | 28.2 | +43.53% |
| Henry ScheinHSIC | $9.17B | 5.8% | 22.7 | +14.05% |
| Sigma HealthcareSIG | $22.55B | 9.2% | 48.3 | +3.55% |
| Sinopharm Group Ltd H1099 | $6.68B | 3.0% | 6.51 | −3.31% |
Same industry or related industries, similar size. Compare Cencora with its competitors · Full profile
